Literature DB >> 22742815

Absence of histological myopathy in chronic myeloid leukemia patients complaining of muscle spasms and myalgia during treatment with nilotinib.

Giovanni Caocci, Maria Antonietta Maioli, Sandra Atzeni, Rachele Piras, Nicola Carboni, Giorgio La Nasa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22742815     DOI： 10.1016/j.leukres.2012.06.006

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  3 in total

1.  Basics and recent advances in peptide and protein drug delivery.

Authors:  Benjamin J Bruno; Geoffrey D Miller; Carol S Lim
Journal:  Ther Deliv       Date:  2013-11

2.  Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation.

Authors:  Osvaldo Contreras; Maximiliano Villarreal; Enrique Brandan
Journal:  Skelet Muscle       Date:  2018-02-20       Impact factor: 4.912

3.  Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Authors:  L Janssen; S J C M Frambach; N A E Allard; M T E Hopman; T J J Schirris; N C Voermans; R J Rodenburg; N M A Blijlevens; S Timmers
Journal:  Leukemia       Date:  2019-03-14       Impact factor: 11.528
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.